Top Small Companies (5,000 employees or less)

FEATUREBest Places to Work 2006: Industry Top Small Companies (5,000 employees or less) Rank in 2006 Rank in 2005 Name/Location Type No. of R&D employees Total No. of New Jobs in 2005 2005 Net Income Significant developments in the past year (among large companies) 1

FEATURE

Best Places to Work 2006: Industry

Top Small Companies (5,000 employees or less)

Rank in 2006	Rank in 2005	Name/Location	Type	No. of R&D employees	Total No. of New Jobs in 2005	2005 Net Income	Significant developments in the past year
(among large companies)
1	1	Tec Laboratories, USA	Skin defense products	11	3	private	Introduced Tecnu Extreme Poison Ivy Scrub
2	2	Transform Pharmaceuticals, USA	Pharmaceutical	86	23	N/A	Acquired by Johnson & Johnson
3	3	Infinity Pharmaceuticals, USA	Pharmaceutical	90	22	private	Formed alliance with Novartis involving cancer drug candidates
4	6	Asterand, USA	Tissue-based services	30	18	$2.4 million (2004)	Merged with Pharmagene
5	-	Raven Biotechnologies, USA	Biotechnology	48	8	none	Started phase I clinical trials for lead drug RAV12
6	8	Lexicon Genetics, USA	Biopharmaceutical	635	21	($36.3 million)	Formed alliance with Genetech
7	-	Amylin Pharmaceuticals, USA	Pharmaceutical	510	550	($206 million)	Received first two FDA product approvals
8	10	Exelixis, USA	Biotechnology	402	42	($83.2 million)	Collaborated with Genentech and GlaxoSmithKline
9	4	Promega, USA	Biotechnology	850 (all depts)	N/A	Over $176 million	N/A
10	-	GeneDx, USA	Genetic testing and diagnosis	35	6	$1.5 million	Added 20 new genetic tests for rare hereditary disorders
11	-	PR Pharmaceuticals, USA	Pharmaceutical	60 (all depts)	N/A	N/A	N/A
12	-	Otsuka Maryland Medicinal Laboratories, USA	Research division of Otsuka Pharmaceuticals	43	4	$963,000	Developing anti-platelet antibodies which might be developed as novel class of anti-thrombotic agents
13	-	Cephalon, USA	Biopharmaceutical	277	549	$167 million	Acquired Zeneus Holdings Limited to gain three marketed products for oncology
14	-	Applied Biosystems, USA	Basic and commerical research	88	32	$1.8 billion	Acquired research products division of Ambion, Inc.
15	-	MedImmune, USA	Biopharmaceutical	484	232	($16.6 million)	Acquired Cellective Therapeutics